Motor neuron disease - Pipeline Insight, 2026

DelveInsight's, "Motor neuron disease - Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor neuron disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Motor neuron disease: Understanding

Motor neuron disease: Overview

Motor neuron disease (MND) is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons, leading to muscle weakness, wasting, cramps, and paralysis. The most common form is Amyotrophic Lateral Sclerosis, alongside other subtypes such as Progressive bulbar palsy, Progressive muscular atrophy, Primary lateral sclerosis, and Spinal muscular atrophy. Most cases are sporadic, although a subset is associated with inherited genetic mutations.

Clinically, MND presents with early symptoms such as limb weakness, muscle twitching, and speech difficulties, which progressively evolve into impaired mobility, swallowing, and respiratory function. In addition to motor decline, patients often experience non-motor symptoms including pain, fatigue, sleep disturbances, mood changes, and cognitive impairment, all of which worsen with disease progression. Diagnosis is primarily clinical, supported by electrophysiological tests and imaging, while management focuses on symptomatic treatment, supportive care, and available disease-modifying therapies.

Motor neuron disease (MND) is driven by a combination of pathological processes such as impaired protein homeostasis, RNA dysregulation, mitochondrial dysfunction, oxidative stress, and glutamate-induced excitotoxicity. Mutations in key genes like SOD1, C9orf72, and FUS promote toxic protein accumulation and defective RNA processing, leading to neuronal damage and disrupted axonal transport. Early neuromuscular junction degeneration, linked to abnormalities in agrin-MuSK-LRP4 signaling and impaired acetylcholine receptor clustering, contributes to the onset of muscle weakness and paralysis. While the majority of cases are sporadic with multifactorial causes, inherited forms show variable penetrance, and heightened neuronal hyperexcitability further increases the susceptibility of motor neurons to degeneration.

Diagnosis of motor neuron disease (MND), including Amyotrophic Lateral Sclerosis, is primarily clinical and based on established criteria such as the revised El Escorial or Gold Coast guidelines, which require evidence of both upper and lower motor neuron involvement and exclusion of alternative conditions. Electromyography is used to detect widespread denervation, while nerve conduction studies and MRI aid in ruling out mimicking disorders; laboratory tests further help exclude metabolic or inflammatory causes, as no single definitive diagnostic test is available.

Management focuses on slowing disease progression and optimizing quality of life. Disease-modifying therapies such as riluzole and edaravone provide modest clinical benefit, with additional targeted options for select genetic subtypes. Treatment is largely supportive and multidisciplinary, addressing mobility, communication, respiratory function, nutrition, and overall symptom control.

"Motor neuron disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Motor neuron disease pipeline landscape is provided which includes the disease overview and Motor neuron disease treatment guidelines. The assessment part of the report embraces, in depth Motor neuron disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Motor neuron disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Motor neuron disease R&D. The therapies under development are focused on novel approaches to treat/improve Motor neuron disease.

Motor neuron disease Emerging Drugs Chapters

This segment of the Motor neuron disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Motor neuron disease Emerging Drugs

Ulefnersen: Ionis Pharmaceuticals/ Otsuka Pharmaceutical

Ulefnersen (formerly ION-363, also known as Jacifusen) is an investigational antisense oligonucleotide (ASO) therapy being developed for the treatment of Amyotrophic Lateral Sclerosis associated with mutations in the FUS gene. The therapy is designed to selectively reduce the production of toxic FUS protein, a key driver of motor neuron degeneration in this genetic subtype of ALS. Preclinical evidence has demonstrated that suppression of FUS expression can prevent motor neuron loss in disease models. By targeting the underlying genetic cause, ulefnersen aims to slow or potentially halt disease progression in patients with FUS-related ALS. The candidate is currently in Phase III clinical development for the treatment of ALS.

COYA 302: Coya Therapeutics

COYA 302 is an investigational biologic combination therapy being developed for the treatment of Amyotrophic Lateral Sclerosis. It comprises a proprietary low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, administered subcutaneously. The therapy is designed to enhance regulatory T-cell (Treg)-mediated anti-inflammatory activity while concurrently suppressing activated monocytes and macrophages. Through this dual mechanism, COYA 302 aims to restore immune balance and mitigate chronic neuroinflammation associated with ALS progression. The candidate is currently in Phase II clinical development.

RNS60: Revalesio Corporation

RNS60 is an investigational, oxygen-enriched saline formulation being developed as a potential disease-modifying and restorative therapy for neurological disorders, including Amyotrophic Lateral Sclerosis. The therapy is designed to enhance mitochondrial biogenesis, improve cellular energy metabolism, and reduce inflammation, thereby protecting neurons and oligodendrocytes while modulating immune responses to restore physiological balance. Supported by robust preclinical evidence, RNS60 has been granted Orphan Drug and Fast Track designations by the US Food and Drug Administration for ALS. The drug is currently in Phase II development for the treatment of Amyotrophic Lateral Sclerosis.

Tegoprubart: Eledon Pharmaceuticals

Tegoprubart (formerly AT-1501), developed by Eledon Pharmaceuticals, is an investigational humanized monoclonal antibody being evaluated for the treatment of Amyotrophic Lateral Sclerosis. The therapy targets CD40 Ligand (CD40L), a key regulator of immune cell activation and neuroinflammatory signaling. By inhibiting CD40L, tegoprubart is designed to suppress neuroinflammatory processes implicated in ALS pathogenesis, thereby potentially slowing disease progression. The candidate is currently in Phase II clinical development.

VTx-002: VectorY Therapeutics

VTx-002 is an investigational small-molecule therapy being developed for the treatment of Amyotrophic Lateral Sclerosis. It is designed to selectively modulate immune signaling pathways implicated in neuroinflammation, a key driver of motor neuron degeneration in ALS. By targeting specific immune mediators, VTx-002 aims to reduce inflammatory responses and protect neuronal integrity. The therapy is expected to help preserve motor function and slow disease progression through its immunomodulatory mechanism. Currently, VTx-002 is in Phase I/II stage of its development for ALS.

SNUG01: SineuGene Therapeutics

SNUG01, developed by SineuGene Therapeutics, is a first-in-class gene therapy being investigated for the treatment of Amyotrophic Lateral Sclerosis. The therapy utilizes a recombinant adeno-associated virus serotype 9 (rAAV9) vector to deliver the human TRIM72 gene to neurons via intrathecal administration. TRIM72 is associated with multiple neuroprotective effects, including reduction of oxidative stress, restoration of mitochondrial function, suppression of neuroinflammation, and promotion of neuronal membrane repair. Through these mechanisms, SNUG01 aims to slow disease progression, particularly in patients with sporadic ALS, which represents the majority of cases. The candidate is currently in Phase I/II clinical development.

LY4256984: Eli Lilly and Company

LY4256984, developed by Eli Lilly and Company, is an investigational biologic being evaluated for the treatment of Amyotrophic Lateral Sclerosis and other neurodegenerative disorders. It is designed to target and modulate neuroinflammatory pathways implicated in motor neuron degeneration by inhibiting key immune mediators involved in neuronal injury. Through this mechanism, the therapy aims to reduce inflammation-driven neurotoxicity and preserve motor function. With its novel immunomodulatory approach, LY4256984 represents a potential next-generation strategy for slowing disease progression in ALS and related conditions. The drug is in Phase I stage of its clinical trial for the treatment of amyotrophic lateral sclerosis.

Motor neuron disease: Therapeutic Assessment

This segment of the report provides insights about the different Motor neuron disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Motor neuron disease
• There are approx. 180+ key companies which are developing the therapies for Motor neuron disease. The companies which have their Motor neuron disease drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals/ Otsuka Pharmaceutical.
• Phases

DelveInsight's report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Motor neuron disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Motor neuron disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Motor neuron disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Motor neuron disease drugs.

Motor neuron disease Report Insights

• Motor neuron disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Motor neuron disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Motor neuron disease drugs?
• How many Motor neuron disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Motor neuron disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Motor neuron disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Motor neuron disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ionis Pharmaceuticals
• Coya Therapeutics
• Revalesio Corporation
• VectorY Therapeutics
• Eli Lilly and Company
• ProJenX
• Seelos Therapeutics
• Time therapeutics
• SOLA Biosciences
• Ceregene
• ProMIS Neurosciences
• Immunity Pharma Ltd.
• NervGen Pharma Corp.
• Dewpoint Therapeutics
• MediciNova
• Eledon Pharmaceuticals
• SineuGene Therapeutics
• Tiziana Life Sciences
• Xalud Therapeutics, Inc.
• Cellenkos
• AL-S Pharma
• Gemma Biotherapeutics
• Ractigen Therapeutics
• Neurizon Therapeutics
• Alcyone Therapeutics
• UniQure N.V.
• Verge Genomics
• 1st Biotherapeutics
• Leal Therapeutics
• Eikonizo Therapeutics

Key Products

• Ulefnersen
• COYA 302
• RNS60
• VTx-002
• LY4256984
• Prosetin
• SLS 009
• TTM 003
• SOL 257
• CERE-130
• PMN267
• IPL699
• NVG 300
• TDP-43
• MN-166
• Tegoprubart
• SNUG01
• Foralumab
• XT-150
• CK0803
• AP-101
• GB221
• RAG-17
• NUZ-001
• EPH101
• AMT-162
• VRG50635
• FB-101
• LTX-002
• EKZ-102